Products are not intended for human or animal consumption, injection, ingestion, diagnosis, treatment, cure, prevention, cosmetic use, or therapeutic use
Novo Nordisk A/S Lead Sponsor Lars Fruergaard Jrgensen Martin Holst Lange Published Research Related to This Trial Citations Coadministered Cagrilintide and Semaglutide in Adults
Patients who dont have a deficiency but are looking to optimize their B12 levels may utilize weekly or monthly injections depending on their response to treatment
The starting dose guide provides additional context for researchers considering different escalation speeds
In the Cagrilintide groups, observed mean weight losses ranged from 5.0% to 9.8% at week 32, slightly less than the 6.1% to 10.8% observed at week 26